Working… Menu
Trial record 4 of 13 for:    VM202

Gene Therapy for the Treatment of Chronic Stable Angina

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01002495
Recruitment Status : Withdrawn (The study was never initiated at any sites.)
First Posted : October 27, 2009
Last Update Posted : February 9, 2015
Information provided by (Responsible Party):
Helixmith Co., Ltd.

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of catheter based injections of VM202 into the heart.

Condition or disease Intervention/treatment Phase
Myocardial Ischemia Genetic: VM202 Phase 1 Phase 2

Detailed Description:
A phase I/II, open label, dose-escalation, multicenter, 12 month study designed to assess the safety and tolerability of catheter based percutaneous myocardial injection of VM202 in patients with chronic refractory myocardial ischemia. The study will consist of three (3) cohorts with a total of 4 subjects enrolled in each cohort. Endocardial injections will be performed with the MyoStar Injection Catheter under guidance of the NOGA XP Cardiac Navigation System.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Chronic Refractory Myocardial Ischemia
Study Start Date : March 2015
Estimated Primary Completion Date : July 2015
Estimated Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Cohort 1
Eight endocardial injection for a total dose of 1mg VM202
Genetic: VM202
Endocardial injections on Day 0.

Experimental: Cohort 2
Eight endocardial injections for a total dose of 2mg VM202
Genetic: VM202
Endocardial injections on Day 0.

Experimental: Cohort 3
Twelve endocardial injections for a total dose of 3mg VM202
Genetic: VM202
Endocardial injections on Day 0.

Primary Outcome Measures :
  1. The primary study objective is to evaluate safety and tolerability of a catheter-based, endocardial injection of different doses of VM202. [ Time Frame: Days 1, 7, 14, 21, 30, 60, and 90, 6 and 12 months ]

Secondary Outcome Measures :
  1. Secondary objectives include the assessment of the angiogenic potential of VM202 [ Time Frame: one month, three months, six months and twelve months ]
  2. Efficacy measures include exercise treadmill test, SPECT, cardiac MRI and change in use of anti-anginal medications. [ Time Frame: Days 1, 7, 14, 21, 30, 60, and 90. 6 and 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 21 years, but less than or equal to 75 years.
  • Stable chronic refractory angina classified as Canadian Cardiovascular Society (CCS) functional class II - IV
  • Left ventricular ejection fraction (LVEF) of ≥30% and ≤ 50%;
  • Clinical signs and symptoms of significant ischemia by treadmill test or Stress imaging (SPECT, Echo or CARDIAC MRI acceptable)
  • Subjects must be able to complete a minimum of 3 minutes, but no more than 10 minutes on a Modified Bruce treadmill protocol.
  • Patients on maximal medical therapy including at least 2 of the following (unless hemodynamic parameters or intolerance contraindicate their use):(a) Long acting nitrate, (b) Beta Blocker or (c) Calcium Channel Blocker (d) Ranolazine. Optimal medical regimen for each subject will be decided by the referring cardiologist or principal investigator. Patients must be on stable medical regimen for 30 days prior to enrollment.
  • Coronary angiogram within 1 year to confirm the presence of coronary disease which is not amenable to standard revascularization procedures.
  • Candidates must not be eligible for any other revascularization procedures. The participant and his/her coronary film must have been discussed with an independent cardiac surgeon and must have been denied for CABG or PTCA. Participants who are marginal or poor candidates for conventional revascularization will be considered eligible if the risks of performing a CABG or PTCA procedure outweigh the potential benefit and/or such a procedure is unlikely to offer a worthwhile clinical benefit. The criteria defining such cases may include, but may not be limited to, the following examples:

    • Diffuse or distal vessel disease
    • Chronic occlusions
    • Unprotected left main stenosis
    • Tortuous or severely angulated vessels
    • Severely calcified vessels
    • Small vessels (< 2.5mm)
  • Subjects with childbearing potential must take acceptable measure to prevent pregnancy during the course of the study.
  • Subject capable of understanding with the protocol and signing the informed consent document prior to any study related procedure.

Exclusion Criteria:

  • Subjects who have undergone a successful revascularization procedure within 6 months of enrollment;
  • MI, unstable angina requiring > 24 hour hospitalization, or percutaneous coronary intervention, within last 90 days;
  • Stroke or TIA within last 180 days;
  • Predominant CHF symptoms;
  • Hemodynamically significant severe primary valvular heart disease, unless corrected by a properly functional prosthetic valve;
  • Uncontrolled hypertension as defined as systolic BP 170 mmHg or diastolic > 90 mmHg at baseline/ screening evaluation;
  • Sustained ventricular tachycardia or automatic implantable cardiodefibrillator (AICD) firing within last 180 days;
  • History of ventricular fibrillation;
  • Use of the MyoStar catheter may not be appropriate for patients with prosthetic valves. Patients with a mechanical valve at risk for injury due to the interventional approach should be excluded;
  • Subjects with any comorbidity that may interfere with the ability to perform a maximal treadmill test (e.g. severe arthritis, musculoskeletal disorders, COPD);
  • Subjects with a history of malignancy, a known active malignancy, or a new screening finding of malignant neoplasm;
  • Patients with family history of colon cancer in any first degree relative unless they have undergone a colonoscopy in the last 12 months with negative findings;
  • Elevated PSA unless prostate cancer has been excluded;
  • Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that preclude standard ophthalmologic examination.

    • Cataract surgery within 6 months of trial;
    • Vascular lesions of the anterior segment of the eye (infection or ulceration of the cornea, rubeotic glaucoma, etc);
    • Vascular lesions of the posterior segment of the eye or proliferative retinopathy in diabetics, macular edema, s/p photocoagulation for macular edema or proliferative retinopathy; nondiabetics with central or branch retinal vascular occlusions, sickle cell retinopathy, ischemic retinopathy due to retinal venous stasis or carotid artery disease);
    • Choroidal new vessels associated with age-related macular degeneration, myopic degeneration, presumed ocular histoplasmosis syndrome, angioid streaks, pseudoxanthoma elasticum, or without ocular disease; and
    • Large elevated choroidal nevi, choroidal vascular tumors (choroidal hemangioma), or melanomas.
  • Chronic inflammatory disease (e.g. Crohn, Rheumatoid Arthritis);
  • Active infectious disease and/or known to have tested positive for human immunodeficiency virus (HIV), human t lymphotrophic virus (HTLV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  • Specific laboratory values at Screening including: Hemoglobin < 9.0, g/dL, WBC < 3,000 cells per microliter, platelet count <75,000/mm3, Creatinine > 2.0 mg/dL, AST and/or ALT > 3 times the upper limit of normal or any other clinically significant lab abnormality which in the opinion of the investigator should be exclusionary;
  • Patients have undergone enhanced external pulsation (EECP) treatment within the last 6 months;
  • Pregnancy or lactation;
  • Severe comorbidity associated with a reduction of life expectancy of less than 1 year;
  • Exposure to any previous experimental angiogenic therapy and/or myocardial laser therapy; or therapy with another investigational drug within 180 days of enrollment or participation in any concurrent study that may confound the results of this study;
  • Major psychiatric disorder in past 6 months;
  • History of recent tobacco abuse (within past < 5 years);
  • Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01002495

Layout table for location information
United States, Illinois
Northwestern Memorial Hospital
Chicago, Illinois, United States
United States, Minnesota
Minneapolis Heart Institute Foundation/ Abbott Northwestern Hospital
Minneapolis, Minnesota, United States, 55407
Sponsors and Collaborators
Helixmith Co., Ltd.

Layout table for additonal information
Responsible Party: Helixmith Co., Ltd. Identifier: NCT01002495     History of Changes
Other Study ID Numbers: VMCAD-001/B
First Posted: October 27, 2009    Key Record Dates
Last Update Posted: February 9, 2015
Last Verified: February 2015
Keywords provided by Helixmith Co., Ltd.:
coronary disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Ischemia
Coronary Artery Disease
Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arterial Occlusive Diseases